Article Hero

AstraZeneca and Johnson & Johnson to continue COVID-19 vaccine trials in the US

1603721245.jpg
Miguel A. Rodriguez
Miguel A. Rodriguez
26 October 2020
Two of the frontrunners in finding a viable medicine against COVID-19 are now able to resume their tests.

The week started with promising news from two of the companies that are working on a potential COVID-19 vaccine.

AstraZeneca and Johnson & Johnson announced that they are ready to resume the temporarily paused vaccine trials. The decision to halt the trails came after each of them reported that a volunteer got unexpectedly sick.

AstraZeneca was authorized by the US Food and Drug Administration to restart the trials after an inquiry showed that the global safety data showed that it's all safe. AstraZeneca's trial was held in September in the UK after a person developed a neurological condition.

Johnson & Johnson's trial was paused earlier this October after a participant reported an "unexpected illness." At the end of last week, JnJ stated that "no clear cause" led to the illness and that "preparations to resume the trial in the United States are now underway." No clear date was specified when the trial will resume, but according to people familiar with the matter, the event will probably occur next week. 

According to government health officials and independent experts, these temporary pauses are setting an example of how safety processes work.

Following the news, AstraZeneca opened 0.87% higher, while Johnson & Johnson is at -0.03%.

Read more about JnJ's situation here!

Sources: edition.cnn.com, finance.yahoo.com

This information/research prepared by Miguel A. Rodriguez does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The research analyst primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views and consequently any person acting on it does so entirely at their own risk.The research provided does not constitute the views of KW Investments Ltd nor is it an invitation to invest with KW Investments Ltd. The research analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.The research analyst in not employed by KW Investments Ltd. You are encouraged to seek advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit that conforms to your specific investment objectives, financial situation, or particular financial needs before making a commitment to invest. The laws of the Republic of Seychelles shall govern any claim relating to or arising from the contents of the information/ research provided. 

Share this article

How did you find this article?

Awful
Ok
Great
Awesome

Read More

Miguel A. Rodriguez
Miguel A. Rodriguez
Financial Writer

Miguel worked for major financial institutions such as Banco Santander, and Banco Central-Hispano. He is a published author of currency trading books.